Intraoperative Alcoholization of the Pituitary Gland Does Not Reduce the Recurrence Rate of Growth Hormone Secreting Pituitary Adenomas

Abstract

Objective Although the role of intraoperative alcoholization of the pituitary gland has been examined for the management of malignant tumor metastases and Rathke's cleft cysts, no such studies have been conducted relating to growth hormone (GH) secreting pituitary tumors, despite the high rate of recurrence in this cohort of patients. Here, we sought to understand the impact of adjunctive intraoperative alcoholization of the pituitary gland on recurrence rates and perioperative complications associated with resection of GH-secreting tumors.

Methods This is a single-institution retrospective cohort study analyzing recurrence rates and complications among patients with GH-secreting tumors who received intraoperative alcoholization of the pituitary gland postresection versus those that did not. Welch's t-tests and analysis of variance (ANOVA) analyses were employed to compare continuous variables between groups, whereas chi-squared tests for independence or Fisher's exact tests were used for comparing categorical variables.

Results A total of 42 patients (n = 22 no alcohol and n = 20 alcohol) were included in the final analysis. The overall recurrence rates did not significantly differ between the alcohol and no alcohol groups (35 and 22.7%, respectively; p = 0.59). The average time to recurrence in the alcohol and no alcohol groups was 22.9 and 39 months, respectively (p = 0.63), with a mean follow-up of 41.2 and 53.5 months (p = 0.34). Complications, including diabetes insipidus, were not significantly different between the alcohol and no alcohol groups (30.0 vs. 27.2%, p = 0.99).

Conclusion Intraoperative alcoholization of the pituitary gland after resection of GH-secreting pituitary adenomas does not reduce recurrence rates or increase perioperative complications.

Keywords

pituitary gland - intraoperative alcoholization - growth hormone–secreting tumors - perioperative complications - pituitary tumor

Publication History

Received: 30 August 2021

Accepted: 30 January 2022

Article published online:
04 March 2022

• Reference

• 1 Lonser RR, Heiss JD, Oldfield EH. Tumor devascularization by intratumoral ethanol injection during surgery. Technical note. J Neurosurg 1998; 88 (05) 923-924
• 2 Greco T. Alcoholization of the pituitary gland in diverse types of neoplasms. Osp Ital Chir 1965; 12 (04) 435-438
• 3 Greco T. Alcoholization of the pituitary gland. advantages of this method in the treatment of advanced malignant tumors and of their recurrence. Urol Int 1965; 19: 54-57
• 4 Sorrentino F. Alcoholization of the pituitary gland in the treatment of prostatic cancer. Urol Int 1965; 19: 47-53
• 5 Cook PR, Campbell FN, Puddy BR. Pituitary alcohol injection for cancer pain. Use in a district general hospital. Anaesthesia 1984; 39 (06) 540-545
• 6 Roberts MT, Henderson RS. Pituitary fossa injection with alcohol for widespread cancer pain. N Z Med J 1981; 93 (675) 1-3
• 7 Lipton S, Miles J, Williams N, Bark-Jones N. Pituitary injection of alcohol for widespread cancer pain. Pain 1978; 5 (01) 73-82
• 8 Lloyd JW, Rawlinson WA, Evans PJ. Selective hypophysectomy for metastatic pain. A review of ethyl alcohol ablation of the anterior pituitary in a regional pain relief unit. Br J Anaesth 1981; 53 (11) 1129-1133
• 9 Fraioli MF, Pagano A, Giovinazzo G, Lunardi P, Fraioli B. Transsphenoidal surgery for secreting pituitary microadenomas: results with intraoperative application of absolute alcohol. Int J Clin Med 2014; 5 (17) 1111-1117
• 10 Chen CJ, Ironside N, Pomeraniec IJ. et al. Microsurgical versus endoscopic transsphenoidal resection for acromegaly: a systematic review of outcomes and complications. Acta Neurochir (Wien) 2017; 159 (11) 2193-2207
• 11 Giustina A, Barkhoudarian G, Beckers A. et al. Multidisciplinary management of acromegaly: a consensus. Rev Endocr Metab Disord 2020; 21 (04) 667-678
• 12 Buttan A, Mamelak AN. Endocrine outcomes after pituitary surgery. Neurosurg Clin N Am 2019; 30 (04) 491-498
• 13 Mortini P, Barzaghi LR, Albano L, Panni P, Losa M. Microsurgical therapy of pituitary adenomas. Endocrine 2018; 59 (01) 72-81
• 14 Fleseriu M, Biller BMK, Freda PU. et al. A Pituitary Society update to acromegaly management guidelines. Pituitary 2021; 24 (01) 1-13
• 15 Starke RM, Raper DM, Payne SC, Vance ML, Oldfield EH, Jane Jr JA. Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission. J Clin Endocrinol Metab 2013; 98 (08) 3190-3198
• 16 Asha MJ, Takami H, Velasquez C. et al. Long-term outcomes of transsphenoidal surgery for management of growth hormone-secreting adenomas: single-center results. J Neurosurg 2019; 133 (05) 1360-1370
• 17 Benveniste RJ, King WA, Walsh J, Lee JS, Naidich TP, Post KD. Surgery for Rathke cleft cysts: technical considerations and outcomes. J Neurosurg 2004; 101 (04) 577-584
• 18 Lillehei KO, Widdel L, Astete CA, Wierman ME, Kleinschmidt-DeMasters BK, Kerr JM. Transsphenoidal resection of 82 Rathke cleft cysts: limited value of alcohol cauterization in reducing recurrence rates. J Neurosurg 2011; 114 (02) 310-317